Mimi Huizinga

Company: ImmunoGen

Job title: SVP, Head of Medical Affairs

Seminars:

Industry Leaders Panel Discussion – Reviewing the Last Year & Creating Strategies to Further Develop ADCs Through 2022 9:30 am

Reviewing how breakthroughs in 2021 are shaping the ADC industry What decision are industry pioneers making to ensure continued progress within the ADC space (technical and business/partnership decisions)? Outlining the biggest challenges that ADC drug developers are facing in taking drugs from the bench to bedside Discussing methods to bring ADCs to earlier-line treatmentRead more

day: Day One

Bringing Mirvetuximab Soravtansine, an FR-alpha Directed ADC, to Patients with Ovarian Cancer 9:00 am

Discussing efficacy and safety of MIRV in FR-alpha high, platinum resistant ovarian cancer Outlining the evolution of the companion diagnostics and impacts on trials Sharing information about on-going trials and next stepsRead more

day: Day One